Feasibility of Ultra-Rapid Exome Sequencing in Critically Ill Infants and Children With Suspected Monogenic Conditions in the Australian Public Health Care System

Abstract

IMPORTANCE Widespread adoption of rapid genomic testing in pediatric critical care requires robust clinical and laboratory pathways that provide equitable and consistent service across health care systems.OBJECTIVE To prospectively evaluate the performance of a multicenter network for ultra-rapid genomic diagnosis in a public health care system. DESIGN, SETTING, AND PARTICIPANTS Descriptive feasibility study of critically ill pediatric patients with suspected monogenic conditions treated at 12 Australian hospitals between March 2018 and February 2019, with data collected to May 2019. A formal implementation strategy emphasizing communication and feedback, standardized processes, coordination, distributed leadership, and collective learning was used to facilitate adoption. EXPOSURES Ultra-rapid exome sequencing. MAIN OUTCOMES AND MEASURESThe primary outcome was time from sample receipt to ultra-rapid exome sequencing report. The secondary outcomes were the molecular diagnostic yield, the change in clinical management after the ultra-rapid exome sequencing report, the time from hospital admission to the laboratory report, and the proportion of laboratory reports returned prior to death or hospital discharge. RESULTSThe study population included 108 patients with a median age of 28 days (range, 0 days to 17 years); 34% were female; and 57% were from neonatal intensive care units, 33% were from pediatric intensive care units, and 9% were from other hospital wards. The mean time from sample receipt to ultra-rapid exome sequencing report was 3.3 days (95% CI, 3.2-3.5 days) and the median time was 3 days (range, 2-7 days). The mean time from hospital admission to ultra-rapid exome sequencing report was 17.5 days (95% CI, 14.6-21.1 days) and 93 reports (86%) were issued prior to death or hospital discharge. A molecular diagnosis was established in 55 patients (51%). Eleven diagnoses (20%) resulted from using the following approaches to augment standard exome sequencing analysis: mitochondrial genome sequencing analysis, exome sequencing-based copy number analysis, use of international databases to identify novel gene-disease associations, and additional phenotyping and RNA analysis. In 42 of 55 patients (76%) with a molecular diagnosis and 6 of 53 patients (11%) without a molecular diagnosis, the ultra-rapid exome sequencing result was considered as having influenced clinical management. Targeted treatments were initiated in 12 patients (11%), treatment was redirected toward palliative care in 14 patients (13%), and surveillance for specific complications was initiated in 19 patients (18%).CONCLUSIONS AND RELEVANCE This study suggests feasibility of ultra-rapid genomic testing in critically ill pediatric patients with suspected monogenic conditions in the Australian public health care system. However, further research is needed to understand the clinical value of such testing, and the generalizability of the findings to other health care settings.

COVID-19 and emergencies in patients with diabetes: two case reports

“…The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak began in China in December 2019 [ 1 ]. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11th, 2020 [ 2 ] and since then there have been over thirty million confirmed cases and over nine hundred thousand deaths worldwide [ 3 ].…”

Ultra‐rapid emergency genomic diagnosis of Donahue syndrome in a preterm infant within 17 hours

“…Several studies have shown a positive impact of early genomic diagnosis on patient counseling and treatment outcomes (Farnaes et al, 2018;Gubbels et al, 2020;Lunke et al, 2020;Meng et al, 2017). Timely genetic diagnoses have led to management changes including shift to palliative care, medication changes, involvement of additional specialties, and the consideration of new experimental therapies (Gubbels et al, 2020;Lunke et al, 2020). Furthermore, by improving care and avoiding unnecessary diagnostics, procedures and medication, rNGS in the NICU has been shown to be cost-effective and even to reduce the health care costs per patient (Farnaes et al, 2018;Stark et al, 2018).…”

Severe perinatal hydrops fetalis in genome edited pigs with a biallelic five base pair deletion of the Marfan syndrome gene, FBN1

“…The incidence is as high as 1 in 200 in some regions (King and Higgs, 2018). Hydrops fetalis has also been associated with Noonan syndrome (mutations of RIT1 or RAF1 gene) (Yaoita et al, 2016; Australian Genomics Health Alliance Acute Care Flagship, 2020), with a glycosylation disorder ( PMM2 gene; Panigrahy et al, 2016) and with biallelic mutations of LARS2 and GLDN (Australian Genomics Health Alliance Acute Care Flagship, 2020). Hydrops fetalis has also been reported in five animal species of a number of breeds ( Table 2 ).…”

“…Hydrops was recently seen in an infant with biallelic mutations in the gliomedin gene, GLDN , located 3 megabases downstream of FBN1 (Australian Genomics Health Alliance Acute Care Flagship, 2020; see Table 1 ). There have been a number of reports of DNA changes in the vicinity of a target sequence associated with the use of CRISPR-Cas9 gene editing (Summers et al, 2019; Alanis-Lobato et al, 2020; Liang et al, 2020; Zuccaro et al, 2020).…”